FENNEC PHARMACEUTICALS INC (FRX.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:FRX - CA31447P1009 - Common Stock
FRX.CA Key Statistics, Chart & Performance
The current stock price of FRX.CA is 11.17 CAD. In the past month the price decreased by -9.41%. In the past year, price increased by 86.79%.
FRX.CA Latest News, Press Relases and Analysis
FRX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 442.17M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 382.96M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 177.20M | ||
| MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 133.46M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 24.25 | 53.19M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 34.18M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 31.54M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 26.75M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 15.64M | ||
| MPH.CA | MEDICURE INC | N/A | 14.09M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.78M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 5.92M |
Related stock screener links
About FRX.CA
Company Profile
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Company Info
FENNEC PHARMACEUTICALS INC
PO Box 13628, 68 Tw Alexander Dr
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: Rostislav Raykov
Employees: 36
Phone: 19196364530
FENNEC PHARMACEUTICALS INC / FRX.CA FAQ
What does FENNEC PHARMACEUTICALS INC do?
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Can you provide the latest stock price for FENNEC PHARMACEUTICALS INC?
The current stock price of FRX.CA is 11.17 CAD. The price decreased by -0.27% in the last trading session.
Does FRX stock pay dividends?
FRX.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of FRX stock?
FRX.CA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is FENNEC PHARMACEUTICALS INC (FRX.CA) expected to grow?
The Revenue of FENNEC PHARMACEUTICALS INC (FRX.CA) is expected to decline by -21.01% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the market cap for FENNEC PHARMACEUTICALS INC?
FENNEC PHARMACEUTICALS INC (FRX.CA) has a market capitalization of 310.86M CAD. This makes FRX.CA a Small Cap stock.
What is the ownership structure of FENNEC PHARMACEUTICALS INC (FRX.CA)?
You can find the ownership structure of FENNEC PHARMACEUTICALS INC (FRX.CA) on the Ownership tab.
FRX.CA Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to FRX.CA. When comparing the yearly performance of all stocks, FRX.CA is one of the better performing stocks in the market, outperforming 79.71% of all stocks.
FRX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FRX.CA. FRX.CA may be in some trouble as it scores bad on both profitability and health.
FRX.CA Financial Highlights
Over the last trailing twelve months FRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.32. The EPS decreased by -475% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.09% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FRX.CA Forecast & Estimates
11 analysts have analysed FRX.CA and the average price target is 19.53 CAD. This implies a price increase of 74.88% is expected in the next year compared to the current price of 11.17.
For the next year, analysts expect an EPS growth of -132665236383229020% and a revenue growth -21.01% for FRX.CA